Morbidity and mortality in systemic lupus erythematosus during a 5-year period: A multicenter prospective study of 1,000 patients

Medicine

Volumn 78, Issue 3, 1999, Pages 167-175

  Cervera, Ricard ^a,l   Khamashta, Munther A ^b   Font, Josep ^a   Sebastiani, Gian Domenico ^c   Gil, Antonio ^d   Lavilla, Paz ^d   Aydintug, A Olcay ^e   Jedryka Góral, Anna ^f   De Ramón, Enrique ^g   Fernández Nebro, Antonio ^g   Galeazzi, Mauro ^h   Haga, Hans Jacob ⁱ   Mathieu, Alessandro ^j   Houssiau, Frédéric ^k   Ruiz Irastorza, Guillermo ^b   Ingelmo, Miguel ^a   Hughes, Graham R V ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e ANKARA UNIVERSITY   (Turkey)

^f INSTITUTE OF RHEUMATOLOGY   (Poland)

^g HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^h UNIVERSITY OF SIENA   (Italy)

ⁱ HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^j UNIVERSITY OF CAGLIARI   (Italy)

^k CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^l HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTHRITIS; ARTICLE; BREAST CANCER; CHILD; FEMALE; FEVER; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; NEUROLOGIC DISEASE; OSTEOPOROSIS; PERICARDITIS; PLEURISY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RASH; RAYNAUD PHENOMENON; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; THROMBOSIS; UTERUS CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EUROPE; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, DIRECT; HUMANS; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0032953105     PISSN: 00257974     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005792-199905000-00003     Document Type: Article

References (46)

1. Abu-Shakra M, Gladman DD, Urowitz MB. Malignancy in systemic lupus erythematosus. Arthritis Rheum 39: 1050-54, 1996.
2. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22: 1259-64, 1995.
3. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22: 1265-70, 1995.
4. American Rheumatism Association glossary committee. Signs and symptoms. Dictionary of the Rheumatic Disease 1: 1-80, 1982.
5. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI: A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-40, 1992.
6. Boumpas DT, Fessler BJ, Austin HA III, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: Emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 123: 42-53, 1995.
7. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Domenech I, Aydintug AO, Jedryka-Goral A, de Ramon E, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ingelmo M, Hughes GRV, and the European Working Party on Systemic Lupus Erythematosus. Systemic lupus erythematosus: Clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. Medicine (Baltimore) 72: 113-24, 1993.
8. Cohen ME, Li EK. Mortality in systemic lupus erythematosus: Active disease is the most important factor. Aust N Z J Med 22: 5-8, 1992.
9. Drenkard C, Villa AR, Alarcon-Segovia D, Perez-Vazquez ME. Influence of the antiphospholipid syndrome in the survival of patients with systemic lupus erythematosus. J Rheumatol 21: 1067-72, 1994.
10. Estes D, Christian C. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore) 50: 85-95, 1971.
11. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC subcommittee for the standardization of lupus anticoagulants. Thromb Haemostas 65: 320-22, 1991.
12. Folomeev M, Alekberova Z. Survival pattern of 120 males with systemic lupus erythematosus. J Rheumatol 17: 856-58, 1990.
13. Fries JF, Weyl S, Hellman HR. Estimating prognosis in disease activity. Am J Med 57, 561-66, 1974.
14. Gharavi AE, Harris EN, Asherson RA, Hughes GRV. Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Ann Rheum Dis 46: 1-6, 1987.
15. Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA Jr, Ziegler G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencer-Green G, Grayzel A, Worth D, Hahn BH, Barnett EV. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum 25: 601-11, 1982.
16. Gladman DD. Prognosis and treatment of systemic lupus erythematosus. Curr Opin Rheumatol 8: 430-37, 1996.
17. Gripenberg M, Helve T. Outcome of systemic lupus erythematosus. A study of 66 patients over 7 years with special reference to the predictive value of anti-DNA antibody determination. Scand J Rheumatol 20: 104-9, 1991.
18. Gudmundsson S, Steinsson K. Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population. J Rheumatol 17: 1162-67, 1990.
19. Harris EN, Williams E, Shah DJ, De Ceulaer K. Mortality of Jamaican patients with systemic lupus erythematosus. Br J Rheumatol 28: 113-17, 1989.
20. Hay EM, Croft P. Predicting outcome in current clinic attenders: A biased view. Ann Rheum Dis 53: 357-58, 1994.
21. Hopkinson N, Doherty M, Powell R. The prevalence and incidence of systemic lupus erythematosus, UK, 1989-90. Br J Rheumatol 32: 110-15, 1993.
22. Jonsson H, Nived O, Sturfelt G. Outcome in systemic lupus erythematosus: A prospective study of patients from a defined population. Medicine (Baltimore) 68: 141-50, 1989.
23. Karlson EW, Daltroy LH, Lew RA, Wright EA, Partridge AJ, Fossel AH, Roberts WN, Stern SH, Straaton KV, Wacholtz MC, Kavanaugh AF, Grosflam JM, Liang MH. The relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. Arthritis Rheum 40: 47-56, 1997.
24. Kellum RE, Hasericke JR. Systemic lupus erythematosus, a statistical evaluation of mortality based on a consecutive series of 229 patients. Arch Intern Med 113: 200-207, 1964.
25. Levy M, Montes de Oca M, Claude-Barron M. Unfavourable outcomes (end-stage renal failure/death) in childhood onset systemic lupus erythematosus. A multicentre study in Paris and its environs. Clin Exp Rheumatol 12(Suppl 10): S63-68, 1994.
26. Lewis RB, Castor CW, Knisley RE, Bole GG. Frequency of neoplasia in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 19: 1256-60, 1976.
27. Massadro L, Martinez ME, Jacobelli S, Villarroel L, Rosenberg H, Rivero S. Survival of Chilean patients with systemic lupus erythematosus. Semin Arthritis Rheum 24: 1-11, 1994.
28. McLaughlin JR, Bombardier C, Farewell VT, Gladman DD, Urowitz MB. Kidney biopsy in systemic lupus erythematosus. III. Survival analysis controlling for clinical and laboratory variables. Arthritis Rheum 37: 559-67, 1994.
29. Mellemkjaer L, Andersen V, Linet MS, Gridley G, Hoover R, Olsen JH. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40: 761-68, 1997.
30. Merrell M, Shulman LE. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1: 12-32, 1955.
31. Nived O, Sturfelt G, Wolheim F. Systemic lupus erythematosus in an adult population in southern Sweden: Incidence/prevalence and validity of ARA revised criteria. Br J Rheumatol 24: 147-54, 1985.
32. Nossent JC. Course and prognosis of systemic lupus erythematosus disease activity index in black caribbean patients. Semin Arthritis Rheum 23: 16-21, 1992.
33. Petri M, Perez-Gutthann S, Longenecher JC, Hochberg M. Morbidity of systemic lupus erythematosus: Role of race and socioeconomic status. Am J Med 91: 345-53, 1991.
34. Petterson T, Pukkala E, Teppo L, Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51: 437-39, 1992.
35. Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klineberg JR. Lupus erythematosus in the 1980s: A survey of 570 patients. Semin Arthritis Rheum 21: 55-64, 1991.
36. Reveille JD, Bartolucci A, Alarcon GS. Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset, black race, and thrombocytopenia, and causes of death. Arthritis Rheum 33: 37-48, 1990.
37. Rubin LA, Urowitz MB, Gladman DD. Mortality in systemic lupus erythematosus: The bimodal pattern revisited. Q J Med 55:87-98, 1985.
38. Seleznick MJ, Fries JF. Variables associated with decreased survival in systemic lupus erythematosus. Semin Arthritis Rheum 21: 73-80, 1991.
39. Studenski S, Allen NB, Caldwell DS, Rice JR, Polisson RP. Survival in systemic lupus erythematosus: A multivariate analysis of demographic factors. Arthritis Rheum 30: 1326-32, 1987.
40. Swaak AJG, Nossent JC, Bronsveld W, Van Rooyen AV, Nieuwenhuys EJ, Theuns L, Smeenk RJT. Systemic lupus erythematosus. I. Outcome and survival: Dutch experience with 110 patients studied prospectively. Ann Rheum Dis 48: 447-54, 1989.
41. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271-77, 1982.
42. Urowitz MB, Bookman AAM, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60: 221-25, 1976.
43. Vlachoyiannopoulos PG, Karassa FB, Karakostas KX, Drosos AA, Moutsopoulos HM. Systemic lupus erythematosus in Greece. Clinical features, evolution and outcome: A descriptive analysis of 292 patients. Lupus 2: 303-12, 1993.
44. Wallace DJ, Podell T, Weiner J, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus: Experience with 609 patients. JAMA 245: 934-38, 1981.
45. Ward MM, Pyun E, Studenski S. Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes. Arthritis Rheum 38: 274-83, 1995.
46. Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort. Arthritis Rheum 38: 1492-99, 1995.